On the Analysis of Cyclic Drug Schedules for Cancer Treatment using Switched Dynamical Systems

Motivated by our prior work on a Triple Negative breast cancer cell line, the focus of this paper is controller synthesis for cancer treatment, through the use of drug scheduling and a switched dynamical system model. Here we study a cyclic schedule of $d$ drugs with maximal waiting times between drug inputs, where each drug is applied once per cycle in any order. We suppose that some of the $d$ drugs are highly toxic to normal cells and that these drugs can shrink the live cancer cell population. The remaining drugs are less toxic to normal cells and can only reduce the growth rate of the live cancer cell population. Also, we assume that waiting time bounds related to toxicity, or to the onset of resistance, are available for each drug. A cancer cell population is said to be stable if the number of live cells tends to zero, as time becomes sufficiently large. In the absence of modeling error, we derive conditions for exponential stability. In the presence of modeling error, we prove exponential stability and derive a settling time, under certain mathematical conditions on the error. We conclude the paper with a numerical example that uses models which were identified on Triple Negative breast cancer cell line data.

[1]  Anders Rantzer,et al.  Computation of piecewise quadratic Lyapunov functions for hybrid systems , 1997, 1997 European Control Conference (ECC).

[2]  S. Rinaldi,et al.  Positive Linear Systems: Theory and Applications , 2000 .

[3]  Jamal Daafouz,et al.  Stability analysis and control synthesis for switched systems: a switched Lyapunov function approach , 2002, IEEE Trans. Autom. Control..

[4]  Hai Lin,et al.  Switched Linear Systems: Control and Design , 2006, IEEE Transactions on Automatic Control.

[5]  Hai Lin,et al.  Stability and Stabilizability of Switched Linear Systems: A Survey of Recent Results , 2009, IEEE Transactions on Automatic Control.

[6]  Xingwen Liu,et al.  Stability Analysis of Switched Positive Systems: A Switched Linear Copositive Lyapunov Function Method , 2009, IEEE Transactions on Circuits and Systems II: Express Briefs.

[7]  Franco Blanchini,et al.  Discrete‐time control for switched positive systems with application to mitigating viral escape , 2011 .

[8]  Guy S. Salvesen,et al.  SnapShot: Caspases , 2011, Cell.

[9]  A. Tolcher,et al.  The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[10]  A. Bardelli,et al.  Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas , 2012, Clinical Cancer Research.

[11]  Patrizio Colaneri,et al.  Optimal therapy scheduling for a simplified HIV infection model , 2013, Autom..

[12]  Patrizio Colaneri,et al.  Switching Strategies to Mitigate HIV Mutation , 2014, IEEE Transactions on Control Systems Technology.

[13]  E. Van Cutsem,et al.  A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors , 2014, Clinical Cancer Research.

[14]  P. Majumder,et al.  Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.

[15]  E. Jokinen,et al.  MEK and PI3K inhibition in solid tumors: rationale and evidence to date , 2015, Therapeutic advances in medical oncology.

[16]  Raja R Srinivas,et al.  Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution , 2016, Cell.

[17]  J. Grilley-Olson,et al.  A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors , 2016, Investigational New Drugs.

[18]  Claire J. Tomlin,et al.  A model of phenotypic state dynamics initiates a promising approach to control heterogeneous malignant cell populations , 2016, 2016 IEEE 55th Conference on Decision and Control (CDC).

[19]  J. Tabernero,et al.  A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer , 2017, Targeted Oncology.